Form 8-K - Current report:
SEC Accession No. 0001193125-24-272853
Filing Date
2024-12-09
Accepted
2024-12-09 06:45:59
Documents
14
Period of Report
2024-12-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d756615d8k.htm   iXBRL 8-K 27549
2 EX-99.1 d756615dex991.htm EX-99.1 29570
  Complete submission text file 0001193125-24-272853.txt   187447

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nuvl-20241205.xsd EX-101.SCH 2511
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nuvl-20241205_lab.xml EX-101.LAB 17956
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nuvl-20241205_pre.xml EX-101.PRE 11238
16 EXTRACTED XBRL INSTANCE DOCUMENT d756615d8k_htm.xml XML 3723
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40671 | Film No.: 241533807
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)